- Home
- PBFS vs NBP Comparison
PBFS vs NBP Comparison
Compare PBFS & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | NBP |
|---|---|---|
| Founded | 1889 | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.8M | 379.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PBFS | NBP |
|---|---|---|
| Price | $13.50 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 7.3K | ★ 620.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.07 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $15,814,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 5.76 | N/A |
| 52 Week Low | $10.60 | $2.93 |
| 52 Week High | $15.18 | $5.19 |
Technical Indicators
Market Signals| Indicator | PBFS | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 36.13 |
| Support Level | $12.89 | N/A |
| Resistance Level | $14.08 | $3.90 |
| Average True Range (ATR) | 0.32 | 0.30 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 20.00 | 3.33 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.